Work

A phase Ib trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in combination with docetaxel

Year: 2009

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2009.27.15_suppl.3547

Authors: G. J. Riely, R. Stoller, M. Egorin, D. Solit, J. Dunbar, A. Savage, J. Walker, D. Grayzel, R. Ross, G. J. Weiss

Institutions: Memorial Sloan Kettering Cancer Center, Infinity Pharmaceuticals (United States), UPMC Hillman Cancer Center

Language: English

Topic: Heat shock proteins research

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3080690847

Cites:

Cited by: 8

Related to: 10